Literature DB >> 34252157

Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study.

Dominik Menges1, Tala Ballouz1, Alexia Anagnostopoulos1, Hélène E Aschmann1, Anja Domenghino1,2, Jan S Fehr1, Milo A Puhan1.   

Abstract

BACKGROUND: Longer-term consequences after SARS-CoV-2 infection are becoming an important burden to societies and healthcare systems. Data on post-COVID-19 syndrome in the general population are required for the timely planning of healthcare services and resources. The objective of this study was to assess the prevalence of impaired health status and physical and mental health symptoms among individuals at least six months after SARS-CoV-2 infection, and to characterize their healthcare utilization.
METHODS: This population-based prospective cohort study (Zurich SARS-CoV-2 Cohort) enrolled 431 adults from the general population with polymerase chain reaction-confirmed SARS-CoV-2 infection reported to health authorities between 27 February 2020 and 05 August 2020 in the Canton of Zurich, Switzerland. We evaluated the proportion of individuals reporting not to have fully recovered since SARS-CoV-2 infection, and the proportion reporting fatigue (Fatigue Assessment Scale), dyspnea (mMRC dyspnea scale) or depression (DASS-21) at six to eight months after diagnosis. Furthermore, the proportion of individuals with at least one healthcare contact after their acute illness was evaluated. Multivariable logistic regression models were used to assess factors associated with these main outcomes.
RESULTS: Symptoms were present in 385 (89%) participants at diagnosis and 81 (19%) were initially hospitalized. At six to eight months, 111 (26%) reported not having fully recovered. 233 (55%) participants reported symptoms of fatigue, 96 (25%) had at least grade 1 dyspnea, and 111 (26%) had DASS-21 scores indicating symptoms of depression. 170 (40%) participants reported at least one general practitioner visit related to COVID-19 after acute illness, and 10% (8/81) of initially hospitalized individuals were rehospitalized. Individuals that have not fully recovered or suffer from fatigue, dyspnea or depression were more likely to have further healthcare contacts. However, a third of individuals (37/111) that have not fully recovered did not seek further care.
CONCLUSIONS: In this population-based study, a relevant proportion of participants suffered from longer-term consequences after SARS-CoV-2 infection. With millions infected across the world, our findings emphasize the need for the timely planning of resources and patient-centered services for post-COVID-19 care.

Entities:  

Year:  2021        PMID: 34252157     DOI: 10.1371/journal.pone.0254523

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  40 in total

1.  Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study).

Authors:  Elizabeth N Mutubuki; Tessa van der Maaden; Ka Yin Leung; Albert Wong; Anna D Tulen; Siméon de Bruijn; Lotte Haverman; Hans Knoop; Eelco Franz; Albert Jan van Hoek; Cees C van den Wijngaard
Journal:  BMJ Open       Date:  2022-07-01       Impact factor: 3.006

2.  Pathophysiology and rehabilitation management of exercise intolerance in COVID-19 patients.

Authors:  Arnengsih Nazir; Indra Putera Hasri
Journal:  Ann Thorac Med       Date:  2022-04-19       Impact factor: 2.535

3.  Health-related quality of life and social determinants of health following COVID-19 infection in a predominantly Latino population.

Authors:  Kathleen R Case; Chen-Pin Wang; Meredith G Hosek; Sarah F Lill; Alexandra B Howell; Barbara S Taylor; James Bridges; Daniel J MacCarthy; Paula Winkler; Joel Tsevat
Journal:  J Patient Rep Outcomes       Date:  2022-06-23

4.  "Long COVID" results after hospitalization for SARS-CoV-2 infection.

Authors:  Marta Rigoni; Emanuele Torri; Giandomenico Nollo; Livia Delle Donne; Sebastiano Rizzardo; Lorenza Lenzi; Andrea Falzone; Susanna Cozzio
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

Review 5.  The human genetic epidemiology of COVID-19.

Authors:  Mari E K Niemi; Mark J Daly; Andrea Ganna
Journal:  Nat Rev Genet       Date:  2022-05-02       Impact factor: 59.581

6.  Persistent COVID-19 symptoms at least one month after diagnosis: A national survey.

Authors:  Imad M Tleyjeh; Tarek Kashour; Muhammad Riaz; Samar A Amer; Nourah AlSwaidan; Laila Almutairi; Rabih Halwani; Abdullah Assiri
Journal:  J Infect Public Health       Date:  2022-04-20       Impact factor: 7.537

7.  Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.

Authors:  Carlo Cervia; Yves Zurbuchen; Patrick Taeschler; Tala Ballouz; Dominik Menges; Sara Hasler; Sarah Adamo; Miro E Raeber; Esther Bächli; Alain Rudiger; Melina Stüssi-Helbling; Lars C Huber; Jakob Nilsson; Ulrike Held; Milo A Puhan; Onur Boyman
Journal:  Nat Commun       Date:  2022-01-25       Impact factor: 14.919

Review 8.  Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis.

Authors:  Lavienraj Premraj; Nivedha V Kannapadi; Jack Briggs; Stella M Seal; Denise Battaglini; Jonathon Fanning; Jacky Suen; Chiara Robba; John Fraser; Sung-Min Cho
Journal:  J Neurol Sci       Date:  2022-01-29       Impact factor: 3.181

Review 9.  Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis.

Authors:  Mohamad Salim Alkodaymi; Osama Ali Omrani; Nader A Fawzy; Bader Abou Shaar; Raghed Almamlouk; Muhammad Riaz; Mustafa Obeidat; Yasin Obeidat; Dana Gerberi; Rand M Taha; Zakaria Kashour; Tarek Kashour; Elie F Berbari; Khaled Alkattan; Imad M Tleyjeh
Journal:  Clin Microbiol Infect       Date:  2022-02-03       Impact factor: 13.310

Review 10.  Post-Acute COVID-19 Syndrome for Anesthesiologists: A Narrative Review and a Pragmatic Approach to Clinical Care.

Authors:  Rafal Kopanczyk; Nicolas Kumar; Thomas Papadimos
Journal:  J Cardiothorac Vasc Anesth       Date:  2021-10-03       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.